SCHEMBL4590045

SCHEMBL4590045

CCN(CC)CCCCNC(=O)c1ccc(C(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.64
HDAC4 P56524 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
ACHE P22303 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
BLM P54132 2/20 0.44
PMP22 Q01453 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4590029 0.93 CXCR4 (0.75) CXCR4DRD2DRD4DRD3NAMPT
SCHEMBL4590055 0.89 CXCR4 (0.58) CXCR4ALDH1A1NAMPTTHRB
SCHEMBL4589207 0.86 CXCR4 (0.56) CXCR4TSHRALDH1A1NAMPT
SCHEMBL1792958 0.85 CXCR4 (0.69) CXCR4HDAC6DRD2DRD4DRD3
SCHEMBL1793629 0.81 CXCR4 (0.59) CXCR4HDAC4HDAC2HDAC8HDAC6
SCHEMBL1794968 0.81 CXCR4 (0.55) CXCR4ALDH1A1NAMPTTHRBSMN1; SMN2
SCHEMBL1795606 0.81 CXCR4 (0.49) CXCR4LMNAALDH1A1MAPK1NAMPT
SCHEMBL1206686 0.80 CXCR4 (0.63) CXCR4DRD2DRD4DRD3NAMPT
SCHEMBL1793506 0.80 CXCR4 (0.48) CXCR4ALDH1A1NAMPT
SCHEMBL1794515 0.79 CXCR4 (0.49) CXCR4TSHRALDH1A1CYP2C19HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885HDAC4 2638/4885HDAC2 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.